Physician profile
Jacob Brenner
NPI 1881369015
$1,780.66
in general payments reported to CMS, 2019-2025
32 companies · $1,143 in 2025
The $1,143 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $34.29 · 2024: $603 · 2025: $1,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,780.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $333.22 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $253.13 | 2024-2025 | Breztri, Bydureon, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $103.70 | 2024-2025 | |
| Amphastar Pharmaceuticals, INC. | $93.81 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $91.60 | 2024-2025 | Gvoke Hypopen, Keveyis |
| Radius Health, INC. | $78.28 | 2025 | Tymlos |
| Recordati_rare_diseases_inc. | $73.77 | 2025 | Isturisa |
| Pfizer INC. | $66.01 | 2025 | |
| Novo Nordisk INC | $64.69 | 2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.01 | 2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $54.19 | 2025 | Opsumit, Uptravi |
| Chiesi USA, INC. | $48.56 | 2024-2025 | Mycapssa |
| Alexion Pharmaceuticals, INC. | $45.52 | 2024-2025 | Strensiq |
| Inspire Medical Systems, INC. | $37.65 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $35.56 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.51 | 2024-2025 | Xifaxan |
| Abbvie INC. | $31.03 | 2024-2025 | |
| Amgen INC. | $30.76 | 2024-2025 | Repatha, Prolia, Evenity |
| Phathom Pharmaceuticals, INC. | $25.53 | 2025 | Voquezna |
| Averitas Pharma INC. | $24.16 | 2025 | Qutenza |
| Astellas Pharma US INC | $22.18 | 2025 | Veozah |
| Amryt Pharma Holdings LTD | $19.83 | 2023 | Mycapssa |
| Merck Sharp & Dohme LLC | $17.95 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Ironwood Pharmaceuticals, INC | $17.37 | 2024 | |
| Kyowa Kirin, INC. | $16.36 | 2024 | Crysvita |
| Exact Sciences Corporation | $16.23 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $15.57 | 2024 | |
| Ascendis Pharma Endocrinology INC | $15.44 | 2024 | |
| Esperion Therapeutics, INC. | $14.66 | 2025 | Nexletol |
| Seqirus USA INC | $14.65 | 2025 | Fluad, Flucelvax |
| Ucb, INC. | $14.46 | 2023 | Cimzia |
| Edwards Lifesciences Corporation | $14.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Brenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.